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CNP in early asymptomatic left ventricular dysfunction (ALVD, NYHA 1)are
undefined. The preeent study investigated the releaee of cardiac ANP, BNP
and CNP in human CHF and determined releaae in ALVD as compared to
symptomatic CHF (NYHA II and Ill). Twenty-two patients (NYHA I to Ill) with
dilated or ischemic cardiomyopathy were studied. Plasma ANP, BNP and
CNP were determined in blood samples from the anterior intetventricular
vein (AIV), the coronary sinus (CS) and the aortic root (Ao) by radioim-
munoessay (Phoenix, Mountain View, CA) in which the difference between
Ao and CS indicates total cardiac release and the difference between Ao
and AIV indicates ventricular release. Cardiac ANP, BNP and CNP release
in ALVD (NYHA Class 1)and symptomatic heart failure (NYHA Class II and
111)are reported below: *p< 0.05 vs Ao.
Ao AIV Cs
NYHA I (n =7)
ANP (pglml) 145 &74 440 + 155* 500 + 152”
BNP (pg/ml) 29& S 30• 9 38& 2
CNP (p@ml) 14+2 13+2 12*2
NYHA 11-111(n = 15)
ANP (p@’ml) ‘ 267 + 100 554 + 159” 524 + 114”
BNP (pg/ml) 53* 12 130 + 27* 10s + 19*
CNP (p@ml) 13+2 14*3 13+2
These data demonstrate: (1) in ALVD, selective ventricular release of
ANP occurs. (2) In symptomatic CHF, ventricular relaasa of ANP and BNP
is significant and (3) CNP is not secreted from the heart in human CHF. In
conclusion, these studies support an important role for ventricular secretion
of ANP and BNP in severe human CHF and differential ventricular secretion
of ANP and BNP in ALVD.
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1783-31Nocturn~lM~l~~onin~~,~~*,~P~ir~~nt~n~
Clinical Effecta of Exoganous Melatonin in Chronic
Heart Failure
F.S.Malik, M.R. Mehra, A. Ali, H.O. Ventura, D.D. Stapleton, P.Brugger,
F.W.Smart. Ochsner Medical Institutions, New Orfeans, LA, USA
Qualitative sleep abnormalities are frequently reported by chronic heart fail-
ure (HF) patients. Melatonin (M), a nocturnally released hormone from the
pineal gland, has been implicated in sleep mediation. In this two-part study,
we first sought to determine abnormalities in circadian M release in chronic
HF by measuring serum M levels in 11 HF patiante (NYHA H; EF <0.2,
without concurrent hepato-renal disease), with complaints of insomnia, and
comparad the levels with age and sex-matched normal controls (n = 11), In
the second part, we studied the effect of nocturnal M replacement (3 mg)
in 6 advanced HF patients (NYHA IV; EF < 0.2) with sleep disturbances
by administering either placebo or melatonin for 4 nights in a double blind,
randomized cross-over study design. Serum for M was drawn et 020+3,0500,
and 141X hours under controlled light and temperature environment. The
patient’s response to intervention was assessed by a modified sleep ques-
tionnaire. Reauks: M levels were significantly suppressed at 0200 and 0500
hours in HF patients comparecfto controls. Mwas undetectable in all daytime
aamplee.
Heart Failure Controls P Value
Melatonin(p@ml) 9.5 * 5.3 37.3 i 5.3 <0.01
Nocturnal replacement in 5 of 6 study patients was associated with sig-
nificant improvement in sleep duration and quality of sleep.
Placsbo Melatonin P
Tme to onset of sleep (rein) 90* 15 30+ 15 <0.05
Durationof sleep (hours) 2*1 5&2 <0,05
Episodesof awakeninghight 3*1 1*1 ns
~me to sleep after awake (rein) 120 l 40 30* 15 <0,05
Two patients reported minor fogginess the day after melatonin. /nfer-
ences: Sleep abnormalities in chronic HF are accompanied by impairment
in the nocturnal release of endogenous melatonin. Furthermore, exogenous
replacement of nightime melatonin improves sleep patferns in severe chronic
heart failure.
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783-4 Effect of Adenosine on the Renal Circulation in
Patients with Chronic Heart Failure
A. Mehra, G. ,Cohen,J.V. Johnson, U. Elkayam. USC School of Medicine,
Los Angelas, CA, USA
Adenosine is produced in the kidney and plays a role in renal vasoregulation
via stimulation of adenosine receptors. However, the effect of exogenous
adenosine on the renal circulation in humans is not well defined. Because of
its potential therapeutic role, we studied the renal circulatory effect of axoge-
nous adenosine in 9 pts with chronic heart failure (CHF) undergoing cardiac
catheterization. Adenosine was infused directly into the renal artery at a dose
calculated to achieve a blood concentration of 10-8 to 10-4M. Main renal
artery cross sectional area (CSA) was measured by intravascular ultrasound
and renal blood flow velocity by intravascular Doppler. Flow velocity integral
(FVI) was measured by planimet~ and renal blood flow was calculated by
the following formula: Heart rate x CSA x FVI. Effect of adenosine was as
follows:
Mean BP (mmHg) CSA (cm2) VT (m) Ranal BloodFlow (mlJmin)
Basalins 91 & 10 0.391 + 0.123 26+ 16 766+ 324
Adenosine 91 + 12 0,3s1 * 0.104 10* s 296 + 144
P Value 0.s 0.3 <0.002 <0.001
Although no change was noted in mean blood pressure (BP) and renal
artery CSA, there was a significant fall in Doppler FVI and renal blood flow.
Conclusion: Adenosine does not have an affect on large (conductance)
renal arIeries but has a marked vasoconstrictive effect on small (resistance)
arteries which leads to a severe reduction in RBF.
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~] lsitSafatoprescribe AaPirinto patienteon
ACE-lnhibitors?
J. Leer, H. Reicher-Reiss, U. Goldbourf, A. Shotan, V. Boyko, S. Gottlieb,
A. Baltler, S. Behar. Cardiology Division, Ben Gurion University Beer
Sheva, keel, Neufeld Cardiac Research Institute, TelHashomec Israel
Several provocative reports have recently suggested that aspirin has dele-
terious interaction with ACE-inhibitors and might attenuate their beneficial
effects upon survival in pts with congestive heart failure (CHF) or coronary
artery disease (CAD). To addrass this issue we analyzed mortality date of
11,575patients with CAD screened for the Bezafibrate Infarction Prevention
(BIP) trial. 1247 pts (11%) were treated with ACE-inhibitors. Of them, 666
pte (54%) used aspirin (ASA+) and 579 did not (ASA–). Both groups were
similar with respect to age, history of diabetes, hypertension, smoking, CHF
and stroke. Female gender, history of Ml and angina were more frequent in
ASA (+) pts. Mortality (4.2 yrs) was lower among ASA (+) pts than ASA (-)
pts (14% vs. 23%; p < 0.001). In multivariate analysis, the use of ASA in pts
on ACE- inhibitore was associated with Iowermonality risk [(relative risk (RR)
0.57; 95% confidence interval (Cl) 0.35-0.93]. Subgroup analysis of 479 pts
with CHF (NYHA class ?2) treated with ACE-inhibitors, revealed 236 ASA
(+) pts and 243 ASA (–) pts. Although clinical characteristics and therapies
were similar, ASA (+) pts experienced lower mortality than ASA (–) pts (17%
vs. 32%; p = 0.001). In multivafiate analysis, administration of ASA was
still associated with lower morfality but with borderline significance [RR-O.61
(0.29-1.28)]. Conclusions: In pts with coronary artery disease, addition of
aspirin to ACE-inhibitors was associated with lower mortality. There was no
excess mortality in subgroup of hearI failure pts treated with ACE-inhibitors
and aspirin. Our findings contradict the claim that aspirin has antagonistic
interaction with ACE-inhibitors.
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~] Massive Fluid Acc.mu,ationD~es NotAffectthe
Pharmacokinetics of the Loop Diuretics Furoaemlde
and Torsemide in Patients With Heart Failure
S.S. Gottlieb, M. Khatfa, D. Wentworth, DS. Roffman, M.L. Fisher,
W. Kramer. Univarsify of Maryland Schools of Medicine and Pharmacy,
Baltimore, MD, USA
Intravenous diuretics are thought to be required in decompensated heart
failure (CHF) because of presumed bowel edema which decraasas or delays
drug absorption. However,oral loop diuretic pharmacokinetics have not been
studied in CHF patients (pts) prior to and after change in fluid status. We
therefore evaluated 37 massively fluid overloaded CHF pts randomized to
receive either furosemide (Fur, 127 t 104 mg) or torsemide (Tor, 65 + 40
mg). There were 26 men & 11women, mean age of 60 (range 35 to 60). All
pts were studied before (Pre) and after (Post) diuresis to euvolemia (at least
